Shaji Kumar
Irene Ghobrial
María-Victoria MateosEvolving diagnostic criteria for high-risk smoldering MM
The Multiple Myeloma Hub spoke with María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES. We asked about the evolving diagnostic criteria for high-risk smoldering MM.
All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
TRANSLATE
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
Masterclass | High-risk smoldering MM: Latest updates for diagnostic criteria and prognosis
The recognition and management of high-risk smoldering multiple myeloma (MM) continues to evolve, with advances in diagnostic criteria and risk stratification informing prognosis and therapeutic decision- -making.
The Multiple Myeloma Hub spoke with María-Victoria Mateos, Irene Ghobrial, and Shaji Kumar to gain their expert insights on the latest updates to diagnostic criteria, current approaches to risk assessment and prognosis, and the rationale for early intervention in patients with high-risk smoldering MM.
.webp)
.webp)
Risk stratification and prognosis in smoldering MM
The Multiple Myeloma Hub spoke to Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US. We asked about risk stratification and prognosis in smoldering multiple myeloma.
.webp)
What is the rationale for early intervention in high-risk smoldering MM?
The Multiple Myeloma Hub spoke with Shaji Kumar, Mayo Clinic, Rochester, US. We asked, What is the rationale for early intervention in high-risk smoldering multiple myeloma?
This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which of the following reflects your thoughts about the feasibility of nursing staff preparing oncology treatments at the bedside at your clinical practice site, as opposed to in the pharmacy?
.webp&w=3840&q=75)